MHC-HM424-100μg / 询价
MHC-HM424-500μg / 询价
MHC-HM424-500μgx2 / 询价
- 客服电话
- 技术支持
Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein
Recombinant Human HPV16 E7(HLA-A*02:01) Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and YMLDLQPET peptide [Accession | P04439-1(HLA-A*02:01)&P61769(B2M)&YMLDLQPET peptide].
The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer is greater than 95% as determined by SEC-HPLC.
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.
HPV16; E7; MHC;
Jiang P, Wang L, Hou B, Zhu J, Zhou M, Jiang J, Wang L, Chen S, Zhu S, Chen J, Zhang L. A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer. Theranostics. 2018 Jun 7;8(13):3544-3558. doi: 10.7150/thno.24607. PMID: 30026865; PMCID: PMC6037027.
